Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
Alzheimer's Disease, Mild Cognitive Impairment, Healthy
About this trial
This is an interventional treatment trial for Alzheimer's Disease focused on measuring Dementia, Mild Cognitive Impairment, MCI, levodopa, learning, enhancement
Eligibility Criteria
Inclusion criteria for patients with dementia: Patients: clinical diagnosis of AD or mild cognitive impairment primary language German Exclusion Criteria for healthy subjects and patients with dementia/MCI: Known allergy to levodopa or tetrazine History of medication/drug abuse Acute nicotine withdrawal or > 15 cigarettes per day > 6 cups/glasses of coffee, caffeine drinks or energy drinks per day > 50 grams of alcohol per day Severe hypertonia (systole >160 mm Hg) Severe arteriosclerosis Diabetes, asthma, or glaucoma Severe hearing disability no focal brain lesions Premorbid depression or psychosis Medication with dopamine agonists or antagonists Parkinsonian symptoms
Sites / Locations
- University of Muenster, Department of NeurologyRecruiting